DBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF
13 July 2018 - 3:30PM
AMF REGULATED INFORMATION
Montrouge, France, July 13, 2018 |
Half-Year Report on
the DBV Technologies Liquidity Contract and Transfer to Oddo
BHF
DBV Technologies (Euronext: DBV -
ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today issued the Half-Year Report on its
liquidity contract with Natixis. Due to the partnership between
Natixis and Oddo BHF, the liquidity contract on DBV Technologies
shares originally entrusted to Natixis, was transferred to Oddo BHF
as of July 2, 2018.
At the close of the liquidity
agreement, the following assets appeared on the liquidity account:
24,313 DBV Technologies shares and € 682,454.94. As of December 29,
2017, the following assets appeared on the liquidity account: 4,939
DBV Technologies shares and € 1,332,828.26. Per the contract dated
June 19, 2018 and for a period of one year, which is tacitly
renewable, Oddo BHF and Natixis will implement DBV Technologies
liquidity and market surveillance contract on ordinary shares, in
accordance with the AMAFI code of Ethics from March 8, 2011
approved by AMF on March 21, 2011.
About DBV
Technologies
DBV Technologies is developing
Viaskin®, a proprietary technology platform with broad potential
applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically
active compounds to the immune system through intact skin. With
this new class of self-administered and non-invasive product
candidates, the Company is dedicated to safely transforming the
care of food allergic patients, for whom there are no approved
treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical
development of Viaskin Egg. DBV is also pursuing a human
proof-of-concept clinical study of Viaskin Milk for the treatment
of Eosinophilic Esophagitis, and exploring potential applications
of its platform in vaccines and other immune diseases. DBV
Technologies has global headquarters in Montrouge, France and New
York, NY. The Company's ordinary shares are traded on segment A of
Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the
SBF120 index, and the Company's ADSs (each representing one-half of
one ordinary share) are traded on the Nasdaq Global Select Market
(Ticker: DBVT).
DBV Investor
Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com
DBV Media
Contact
Raul Damas
Partner, Brunswick Group
+1-212-333-3810
DBV@brunswickgroup.com
PDF version
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: DBV Technologies via Globenewswire
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Apr 2024 to May 2024
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From May 2023 to May 2024